Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.
The FDA gave the go-ahead to Novocure for its tumor-treating electric fields device that targets advanced pancreatic cancer ...
Zacks Investment Research on MSN
Will NovoCure (NVCR) report negative earnings next week? What you should know
The market expects NovoCure (NVCR) to deliver a year-over-year increase in earnings on higher revenues when it reports ...
The Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain ...
FDA leaders framed the approval as a step forward for a cancer that has seen few therapeutic breakthroughs, stressing that ...
Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer ...
The sentiment is ecstatic regarding this de-risking event. Will the stock maintain these gains, or is this a typical 'sell the news' occurrence?
The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of ...
The FDA approved Optune Pax (Novocure), a first-in-class portable device that delivers tumor-treating fields (TTFields) to ...
NovoCure (NVCR) is back in focus after the U.S. Food and Drug Administration approved its Optune Pax device for adult patients with locally advanced pancreatic cancer, following positive Phase 3 ...
Winning approval to target the 15,000 U.S. patients with locally advanced pancreatic cancer is the first step in a broader expansion in the tumor type.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results